Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Apple Turns 50: From Garage Startup to AI Crossroads 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Britain Courts Anthropic Amid US Defense Department Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
CLEVELAND, Oct. 11, 2016 -- Athersys, Inc. (Nasdaq:ATHX) will release its third quarter 2016 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 9, 2016, and host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
| Date | November 9, 2016 |
| Time | 4:30 p.m. (Eastern Time) |
| Telephone access: US and Canada | (800) 273-1254 |
| Telephone access: International | (973) 638-3440 |
| Access code | 97839505 |
| Live webcast | www.athersys.com under Investors section |
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on November 23, 2016 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 97839505.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
ATH-G
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected]
